Bio-Techne Corp
NASDAQ:TECH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
62.12
84.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Bio-Techne Corp
Bio-Techne Corp
Total Receivables
Bio-Techne Corp
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bio-Techne Corp
NASDAQ:TECH
|
Total Receivables
$223.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
14%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Total Receivables
$9.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
17%
|
CAGR 10-Years
15%
|
|
|
Danaher Corp
NYSE:DHR
|
Total Receivables
$4.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
2%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
Total Receivables
$637.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
4%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Total Receivables
$1.3B
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Total Receivables
$3.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
5%
|
CAGR 10-Years
12%
|
|
Bio-Techne Corp
Glance View
Bio-Techne Corp. began its journey with a clear focus: to bridge the gap between biological research and practical applications, a mission that it continues to pursue with zeal. At its core, Bio-Techne operates as a pioneer in the production and distribution of biotechnology products, catering to the needs of the scientific community across the globe. The company specializes in providing essential tools for life sciences research, including proteins, antibodies, and reagents, empowering researchers to explore and innovate in fields ranging from cancer biology to neuroscience. These offerings are developed with meticulous care and a deep understanding of the scientific process, which positions Bio-Techne as a trusted ally to laboratories and research institutions worldwide. The financial heartbeat of Bio-Techne lies in its diverse portfolio, which extends into clinical diagnostics and genomics, segments that are critical in an era of personalized medicine and rapid technological advancement in healthcare. The company's revenue streams are robust, driven by a strategic blend of direct sales and collaborations with major pharmaceutical and biotech companies. Furthermore, Bio-Techne smartly leverages its acquisitions to fortify its market position, enhancing its capabilities and expanding its product lines. This agility and foresight not only enable Bio-Techne to sustain its growth trajectory but also to continually meet the ever-evolving demands of a fast-paced, innovation-driven industry.
See Also
What is Bio-Techne Corp's Total Receivables?
Total Receivables
223.7m
USD
Based on the financial report for Sep 30, 2024, Bio-Techne Corp's Total Receivables amounts to 223.7m USD.
What is Bio-Techne Corp's Total Receivables growth rate?
Total Receivables CAGR 10Y
14%
Over the last year, the Total Receivables growth was 9%. The average annual Total Receivables growth rates for Bio-Techne Corp have been 15% over the past three years , 13% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet
